Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.35 |
| ▸ | CBS | P35520 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600786 | 0.95 | TSHR (0.38) | TSHRCTHCBSTHPOCYP1A2 | |
| SCHEMBL6645229 | 0.83 | TSHR (0.36) | TSHRCTHCBSTHPOCYP1A2 | |
| SCHEMBL29016903 | 0.83 | TDP1 (0.36) | CYP1A2TP53ALDH1A1GAACYP2C9 | |
| SCHEMBL29016960 | 0.83 | TDP1 (0.36) | CYP1A2TP53ALDH1A1GAACYP2C9 | |
| SCHEMBL7159806 | 0.83 | TDP1 (0.36) | CYP1A2TP53ALDH1A1GAACYP2C9 | |
| SCHEMBL1025317 | 0.79 | TSHR (0.34) | TSHRTP53 | |
| SCHEMBL29016906 | 0.79 | TSHR (0.34) | TSHRTP53 | |
| SCHEMBL29016924 | 0.79 | TSHR (0.34) | TSHRTP53 | |
| SCHEMBL11658193 | 0.76 | GABRR1 (0.34) | TP53KMT2A | |
| SCHEMBL31634142 | 0.74 | TSHR (0.40) | TSHRCYP1A2TP53ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | disclosed |
| US-20150283092-A1 | DRUG DELIVERY COMPOSITION | ALKERMES PHARMA IRELAND LTD (IE) | 2015-10-08 | — | — | US | disclosed |
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-07-23 | — | — | US | disclosed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | disclosed |
| US-20140242063-A1 | PHARMACEUTICAL COMPOSITIONS | VALEANT LABORATORIES INTERNATIONAL BERMUDA (BM) | 2014-08-28 | — | — | US | disclosed |
| US-20140170216-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | VALEANT INTERNATIONAL BERMUDA (BM) | 2014-06-19 | — | — | US | disclosed |
| US-20140030249-A1 | Pharmaceutical Compositions | VALEANT INTERNATIONAL BERMUDA (BM) | 2014-01-30 | — | — | US | disclosed |
| US-8604085-B2 | Bupropion hydrobromide polymorphs | VALEANT INTERNATIONAL BERMUDA (BM) | 2013-12-10 | — | — | US | disclosed |
| US-20130266650-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | JACKSON GRAHAM (BB) | 2013-10-10 | — | — | US | disclosed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4200098-A | Osmotic system with distribution zone for dispensing beneficial agent | ALZA CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
| US-4160452-A | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina | ALZA CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4160020-A | CELLULOSE ESTERS, CELLULOSE ETHERS | ALZA CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | SLC6A2, SLC6A3, SLC6A11 | TSHR 1186/4885CTH 1013/4885CBS 1192/4885 |
| US-20140170216-A1 | BUPROPION HYDROBROMIDE POLYMORPHS | SLC6A3, GABBR1, SLC6A2 | TSHR 3352/4885CTH 543/4885CBS 1251/4885 |
| US-20140030249-A1 | Pharmaceutical Compositions | HTT, ATXN10, TTR | TSHR 117/4885CTH 1509/4885CBS 992/4885 |
| US-20140242063-A1 | PHARMACEUTICAL COMPOSITIONS | HTT, ATXN10, TTR | TSHR 117/4885CTH 1509/4885CBS 992/4885 |
| US-20130266650-A1 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS | GABBR1, SLC6A2, GABBR2 | TSHR 1150/4885CTH 208/4885CBS 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.